Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazyar Shadman

Showing results (11-20 of 224) with videos related to

Pageof 23
Sort By:
Journal of Oncology Practice|April 11, 2019
Influenza in the AirMazyar Shadman, Steven A Pergam
Mediterranean Journal of Hematology and Infectious Diseases|September 20, 2014
Hematopoietic Cell Transplantation for Older Patients with MDSMazyar Shadman, H Joachim Deeg
Hematology/Oncology Clinics of North America|June 27, 2021
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and BeyondMazyar Shadman, David G Maloney
Blood|October 30, 2025
Bispecific antibodies in action: the reality of engagementMazyar Shadman, Ajay K Gopal
Expert Review of Hematology|April 4, 2013
Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemiaMazyar Shadman, Elihu H Estey
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Blood Advances|March 11, 2025
Consensus in CLL: global needs matterMazyar Shadman, Bita Fakhri, Nitin Jain
Expert Opinion on Pharmacotherapy|August 16, 2022
Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemiaAlycia Hatashima, Mehdi Karami, Mazyar Shadman
Cancers|January 25, 2025
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia TreatmentAlycia Hatashima, Mazyar Shadman, Vikram Raghunathan
Expert Opinion on Pharmacotherapy|March 1, 2021
Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so farLauren Held, Chloe Siu, Mazyar Shadman
Pageof 23

Showing results (11-20 of 224) with videos related to

Sort By:
Pageof 23
Journal of Oncology Practice|April 11, 2019
Influenza in the AirMazyar Shadman, Steven A Pergam
Mediterranean Journal of Hematology and Infectious Diseases|September 20, 2014
Hematopoietic Cell Transplantation for Older Patients with MDSMazyar Shadman, H Joachim Deeg
Hematology/Oncology Clinics of North America|June 27, 2021
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and BeyondMazyar Shadman, David G Maloney
Blood|October 30, 2025
Bispecific antibodies in action: the reality of engagementMazyar Shadman, Ajay K Gopal
Expert Review of Hematology|April 4, 2013
Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemiaMazyar Shadman, Elihu H Estey
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Blood Advances|March 11, 2025
Consensus in CLL: global needs matterMazyar Shadman, Bita Fakhri, Nitin Jain
Expert Opinion on Pharmacotherapy|August 16, 2022
Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemiaAlycia Hatashima, Mehdi Karami, Mazyar Shadman
Cancers|January 25, 2025
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia TreatmentAlycia Hatashima, Mazyar Shadman, Vikram Raghunathan
Expert Opinion on Pharmacotherapy|March 1, 2021
Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so farLauren Held, Chloe Siu, Mazyar Shadman
Pageof 23